Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

NCT06178211 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Immunotherapy: Adebrelimab
DRUG: chemotherapy: carboplatin plus nab-paclitaxel

Sponsor

Shanghai Chest Hospital